BiomX (PHGE)

• Market cap: $14.6M
• 1 day: 0.18%
• 5 days: 1.42%
• 1 month: 27.27%
• 3 months: 6.60%
• 6 months: -31.11%
• Year to date: -29.80%
• 1 year: -58.56%
• 5 years: -99.09%
• 10 years: -99.43%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Employees: 57

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

10% less funds holding

Funds holding: 21 [Q1] → 19 (-2) [Q2]

11.81% less ownership

Funds ownership: 53.59% [Q1] → 41.77% (-11.81%) [Q2]

34% less capital invested

Capital invested by funds: $7.44M [Q1] → $4.92M (-$2.53M) [Q2]

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $15 2,622% upside
• Avg. target: $15 2,622% upside
• High target: $15 2,622% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis

2,622% upside $15

Buy Reiterated

20 Aug 2025